Abstract
Abnormal expression of ADAM29 has been frequently reported in several cancers, however, its role in clear cell renal cell carcinoma (ccRCC) has not evaluated in detail. Herein, we attempt to determine the biological role and the action mechanism of ADAM29 in ccRCC. Bioinformatics analysis based on the ccRCC RNA-Seq dataset from TCGA database revealed that ADAM29 was up-expressed in ccRCC tissues by comparison with normal tissues. And a significant increase of ADAM29 expression was also observed in 3 ccRCC cell lines (UT33A, Caki-1, and786-O) in comparison with normal cell line. Besides, high level of ADAM29 was found to be connected with the poor prognosis and could be considered as an independent prognosticator for patients with ccRCC. Furthermore, functional experiments in vitro demonstrated that ADAM29 promoted the growth, invasion and migration of ccRCC cells. Moreover, Western blot assays indicated that ADAM29 was positively correlated with the level of proliferation-related proteins Cyclin D1 and PCNA and motion-related proteins MMP9 and Snail. Our data indicate that ADAM29 acts as an oncogene that increases tumour cells proliferation, invasion and migration partly by regulating the expression of Cyclin D1/PCNA/MMP9/Snail, suggesting that ADAM29 may become a prognosticator and therapeutic candidate for ccRCC.
Additional information
Notes on contributors
Shun-Lai Li
Shun-Lai Li is a associate chief physician of urology department of the Fifth People's Hospital of Jinan, specializes in the diagnosis and treatment of urological tumor, stone, and prostatic hyperplasia.
Ting-Qi Jiang
Ting-Qi Jiang is a chief physician of urology department of the Fifth People's Hospital of Jinan, specializes in the diagnosis and treatment of urological tumor and stone.
Qing-Wei Cao
Qing-Wei Cao is a chief physician of urology department of Shandong Provincial Hospital, specializes in the diagnosis and treatment of renal tumor, ureteral tumor, and bladder tumor.
Shan-Mei Liu
Shan-Mei Liu is a chief physician of urology department of the Fifth People's Hospital of Jinan, specializes in prostate cancer endocrine therapy.